Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Gubens on Prevalence of EGFR/ALK/ROS1 and PD-L1 Expression in NSCLC

May 1st 2017

Matthew Gubens, MD, an assistant professor of thoracic oncology at the University of California San Francisco, discusses the prevalence of patients with non–small cell lung cancer (NSCLC) who harbor mutations in EGFR/ALK/ROS1 as well as PD-L1 expression.

Dr. Osborne Discusses Targeting the HER2 Pathway in Breast Cancer

April 18th 2017

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses targeting the HER2 pathway in breast cancer.

Expert Emphasizes Significance of Genetic Testing in Ovarian Cancer

April 14th 2017

Mike Janicek, MD sheds light on why physicians are slow to educate patients on testing, the detection of genes aside from BRCA1/2, and the lesser-known benefits of getting genetic testing early on in a diagnosis.

Dr. Quinn on Combinations of Targeted Therapy in RCC

April 11th 2017

David I. Quinn, MD, MBBS, associate professor of Medicine, medical director of USC Norris Cancer Hospital, on combinations of targeted therapies for patients with renal cell carcinoma (RCC).

Dr. Janni on the Benefits of Targeted Therapies for HER2-Positive Breast Cancer

April 5th 2017

Wolfgang Janni, MD, PhD, University of Ulm, discusses the benefits of HER2-targeted therapies for patients with all stages of HER2-positive breast cancer.

Novel Agents Continue to Make Mark in Lung Cancer

March 30th 2017

Mark B. Stoopler, MD, discusses ongoing developments in immunotherapy and his vision for the future of non-small cell lung cancer treatment.

Dr. Jackman on Overcoming Resistance to EGFR Inhibitors in Lung Cancer

March 27th 2017

David M. Jackman, MD, medical director of Clinical Pathways, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses overcoming resistance to EGFR inhibitors in non–small cell lung cancer (NSCLC).

Dr. Swisher on Efficacy Results of ARIEL 2 Study in Ovarian Cancer

March 24th 2017

Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the results of the ARIEL2 trial in patients in patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma with a germline or somatic BRCA mutation.

Maintenance Olaparib Shows Impressive PFS Benefit for BRCA+ Ovarian Cancer

March 15th 2017

Maintenance therapy with olaparib showed a 70% reduction in the risk of progression or death compared with placebo for patients with platinum-sensitive, relapsed, BRCA-mutant ovarian cancer.

Carboplatin Hypersensitivity Linked to BRCA Deficiency in Ovarian Cancer

March 14th 2017

Treatment with a carboplatin desensitization regimen led to improved overall survival in patients with BRCA-proficient ovarian cancer.

MMR Deficiency Linked to PD-L1 Expression in Endometrial Cancer

March 14th 2017

Mismatch repair-deficient endometrial cancers exhibited significantly higher levels of PD-L1 expression compared with MMR-intact tumors.

New Insights Into Rucaparib Activity in Ovarian Cancer

March 13th 2017

The PARP inhibitor rucaparib slowed progression of relapsed BRCA-mutant ovarian cancer regardless of whether the mutations were somatic or germline, a new analysis of a phase II trial showed.

Gomella Discusses Ongoing Progress With Genetic Testing in Prostate Cancer

March 11th 2017

Leonard Gomella, MD, discusses the current state and critical next steps for optimizing genetic testing in prostate cancer.

Butterfly Effect May Foil Genomic Medicine

March 11th 2017

The so-called butterfly effect, in which a small creature can cause something on the scale of an earthquake merely by flapping its wings, is fodder for debate on whether the digital revolution in medicine can deliver on its promise for precision medicine.

Breast Surgeons Essential for Effective Genetic Testing

March 10th 2017

It is imperative that surgeons remain involved in genetic counseling to meet the immense unmet need that exists for patients with breast cancer, given a shortage of available genetic counselors.

Petrylak Discusses Significance of Genetic Testing in Prostate Cancer

March 8th 2017

Daniel Petrylak, MD, discusses the significance of genetics in the future of prostate cancer care and highlights emerging treatments and challenges in the field.

Dr. Kane on High-Penetrance Genetic Syndromes in Prostate Cancer

March 8th 2017

Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses high-penetrance genetic syndromes in patients with prostate cancer.

Dr. Drilon on NTRK Rearrangement in Lung Cancer

March 3rd 2017

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses NTRK rearrangement in patients with lung cancer.

Expert Discusses Biomarkers for PARP Inhibitors in Ovarian Cancer

February 20th 2017

Dr. Elizabeth Swisher discusses biomarkers for PARP inhibitors and the evolving role of these agents in ovarian cancer.

Olaparib Improves PFS in Phase III BRCA+ Breast Cancer Trial

February 17th 2017

The PARP inhibitor olaparib improved progression-free survival versus standard chemotherapy in patients with BRCA-positive, HER2-negative breast cancer, according to findings from the phase III OLYMPIAD trial.